Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 745 to 756 of 756 entries
Sorted by: Best Match Show Resources per page
Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Wang L, Chu X, Wang J, An L, Liu Y, Li L, Xu J.
PMID: 33938209
Turk J Haematol. 2021 Aug 25;38(3):188-194. doi: 10.4274/tjh.galenos.2021.2021.0009. Epub 2021 May 03.

OBJECTIVE: This study aimed to investigate the clinical characteristics of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) according to the 2016 World Health Organization classification and the preferred therapy for patients with AML-MRC aged 60-75 years.MATERIALS AND METHODS: We...

Cite
Wang L, Chu X, Wang J, et al. Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients. Turk J Haematol. 2021;38(3):188-194doi: 10.4274/tjh.galenos.2021.2021.0009.
Wang, L., Chu, X., Wang, J., An, L., Liu, Y., Li, L., & Xu, J. (2021). Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients. Turkish journal of haematology : official journal of Turkish Society of Haematology, 38(3), 188-194. https://doi.org/10.4274/tjh.galenos.2021.2021.0009
Wang, Lei, et al. "Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients." Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 38,3 (2021): 188-194. doi: https://doi.org/10.4274/tjh.galenos.2021.2021.0009
Wang L, Chu X, Wang J, An L, Liu Y, Li L, Xu J. Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients. Turk J Haematol. 2021 Aug 25;38(3):188-194. doi: 10.4274/tjh.galenos.2021.2021.0009. Epub 2021 May 03. PMID: 33938209; PMCID: PMC8386305.
Copy Download .nbib Format: NLM
Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

British journal of cancer

Karsa M, Kosciolek A, Bongers A, Mariana A, Failes T, Gifford AJ, Kees UR, Cheung LC, Kotecha RS, Arndt GM, Haber M, Norris MD, Sutton R, Lock RB, Henderson MJ, Somers K.
PMID: 33837299
Br J Cancer. 2021 Jul;125(1):55-64. doi: 10.1038/s41416-021-01332-x. Epub 2021 Apr 09.

BACKGROUND: The prognosis for high-risk childhood acute leukaemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients.METHODS: A high-throughput phenotypic screen of...

Cite
Karsa M, Kosciolek A, Bongers A, et al. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. Br J Cancer. 2021;125(1):55-64doi: 10.1038/s41416-021-01332-x.
Karsa, M., Kosciolek, A., Bongers, A., Mariana, A., Failes, T., Gifford, A. J., Kees, U. R., Cheung, L. C., Kotecha, R. S., Arndt, G. M., Haber, M., Norris, M. D., Sutton, R., Lock, R. B., Henderson, M. J., & Somers, K. (2021). Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. British journal of cancer, 125(1), 55-64. https://doi.org/10.1038/s41416-021-01332-x
Karsa, Mawar, et al. "Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin." British journal of cancer vol. 125,1 (2021): 55-64. doi: https://doi.org/10.1038/s41416-021-01332-x
Karsa M, Kosciolek A, Bongers A, Mariana A, Failes T, Gifford AJ, Kees UR, Cheung LC, Kotecha RS, Arndt GM, Haber M, Norris MD, Sutton R, Lock RB, Henderson MJ, Somers K. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. Br J Cancer. 2021 Jul;125(1):55-64. doi: 10.1038/s41416-021-01332-x. Epub 2021 Apr 09. PMID: 33837299; PMCID: PMC8257682.
Copy Download .nbib Format: NLM
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.

Pediatric blood & cancer

Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R.
PMID: 34596937
Pediatr Blood Cancer. 2021 Dec;68(12):e29281. doi: 10.1002/pbc.29281. Epub 2021 Oct 01.

BACKGROUND: High-risk pediatric acute myeloid leukemia confers a poor prognosis, and alternative strategies are needed to improve outcomes. We hypothesized that intensifying induction on the AAML1031 clinical trial would improve outcomes compared to the predecessor trial AAML0531.METHODS: Patients on...

Cite
Elgarten CW, Wood AC, Li Y, et al. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021;68(12):e29281doi: 10.1002/pbc.29281.
Elgarten, C. W., Wood, A. C., Li, Y., Alonzo, T. A., Brodersen, L. E., Gerbing, R. B., Getz, K. D., Huang, Y. V., Loken, M., Meshinchi, S., Pollard, J. A., Sung, L., Woods, W. G., Kolb, E. A., Gamis, A. S., & Aplenc, R. (2021). Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric blood & cancer, 68(12), e29281. https://doi.org/10.1002/pbc.29281
Elgarten, Caitlin W, et al. "Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group." Pediatric blood & cancer vol. 68,12 (2021): e29281. doi: https://doi.org/10.1002/pbc.29281
Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 Dec;68(12):e29281. doi: 10.1002/pbc.29281. Epub 2021 Oct 01. PMID: 34596937.
Copy Download .nbib Format: NLM
The cure of leukemia through the optimist's prism.

Cancer

Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ.
PMID: 34614211
Cancer. 2021 Oct 06; doi: 10.1002/cncr.33933. Epub 2021 Oct 06.

Progress is occurring at a dizzying rate across all leukemias. Since the authors' review of the topic in Cancer in 2018, numerous discoveries have been made that have improved the therapy and outcomes of several leukemia subsets. Hairy cell...

Cite
Kantarjian HM, Jain N, Garcia-Manero G, et al. The cure of leukemia through the optimist's prism. Cancer. 2021;doi: 10.1002/cncr.33933.
Kantarjian, H. M., Jain, N., Garcia-Manero, G., Welch, M. A., Ravandi, F., Wierda, W. G., & Jabbour, E. J. (2021). The cure of leukemia through the optimist's prism. Cancer, . https://doi.org/10.1002/cncr.33933
Kantarjian, Hagop M, et al. "The cure of leukemia through the optimist's prism." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33933
Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer. 2021 Oct 06; doi: 10.1002/cncr.33933. Epub 2021 Oct 06. PMID: 34614211.
Copy Download .nbib Format: NLM
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course.

Cancers

Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR.
PMID: 34885231
Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236122.

Although treatment options of acute myeloid leukemia (AML) have improved over the recent years, prognosis remains poor. Better understanding of the molecular mechanisms influencing and predicting treatment efficacy may improve disease control and outcome. Here we studied the expression,...

Cite
Clar KL, Weber LM, Schmied BJ, et al. Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236122.
Clar, K. L., Weber, L. M., Schmied, B. J., Heitmann, J. S., Marconato, M., Tandler, C., Schneider, P., & Salih, H. R. (2021). Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers, 13(23), . https://doi.org/10.3390/cancers13236122
Clar, Kim L, et al. "Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236122
Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR. Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236122. PMID: 34885231.
Copy Download .nbib Format: NLM
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia.

Cancers

Legrand N, Pradier A, Poulain L, Mouche S, Birsen R, Larrue C, Simonetta F, Tamburini J.
PMID: 34885077
Cancers (Basel). 2021 Nov 27;13(23). doi: 10.3390/cancers13235966.

The treatment of acute myeloid leukemia (AML) remains a challenge especially among the elderly. The Bcl-2 inhibitor venetoclax recently showed significant survival benefits in AML patients when combined to low-dose cytarabine or azacitidine. Bcl-2 inhibition initiate mitochondrial apoptosis, but...

Cite
Legrand N, Pradier A, Poulain L, et al. AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13235966.
Legrand, N., Pradier, A., Poulain, L., Mouche, S., Birsen, R., Larrue, C., Simonetta, F., & Tamburini, J. (2021). AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. Cancers, 13(23), . https://doi.org/10.3390/cancers13235966
Legrand, Noémie, et al. "AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13235966
Legrand N, Pradier A, Poulain L, Mouche S, Birsen R, Larrue C, Simonetta F, Tamburini J. AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. Cancers (Basel). 2021 Nov 27;13(23). doi: 10.3390/cancers13235966. PMID: 34885077; PMCID: PMC8656606.
Copy Download .nbib Format: NLM
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?.

Current oncology reports

Tang K, Schuh AC, Yee KW.
PMID: 34350512
Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9.

PURPOSE OF REVIEW: With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the...

Cite
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021;23(10):120doi: 10.1007/s11912-021-01108-9.
Tang, K., Schuh, A. C., & Yee, K. W. (2021). 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Current oncology reports, 23(10), 120. https://doi.org/10.1007/s11912-021-01108-9
Tang, Kenny, et al. "3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?." Current oncology reports vol. 23,10 (2021): 120. doi: https://doi.org/10.1007/s11912-021-01108-9
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9. PMID: 34350512.
Copy Download .nbib Format: NLM
Which novel agents will have a clinically meaningful impact in AML at diagnosis?.

Best practice & research. Clinical haematology

Perl AE.
PMID: 33762111
Best Pract Res Clin Haematol. 2021 Mar;34(1):101257. doi: 10.1016/j.beha.2021.101257. Epub 2021 Feb 13.

New drug approvals now afford AML physicians a wider choice of initial treatment options than ever before. Although chemotherapy for AML is by no means ready to be replaced entirely by novel agents, the role of traditional cytotoxics in...

Cite
Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best Pract Res Clin Haematol. 2021;34(1):101257doi: 10.1016/j.beha.2021.101257.
Perl, A. E. (2021). Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best practice & research. Clinical haematology, 34(1), 101257. https://doi.org/10.1016/j.beha.2021.101257
Perl, Alexander E. "Which novel agents will have a clinically meaningful impact in AML at diagnosis?." Best practice & research. Clinical haematology vol. 34,1 (2021): 101257. doi: https://doi.org/10.1016/j.beha.2021.101257
Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best Pract Res Clin Haematol. 2021 Mar;34(1):101257. doi: 10.1016/j.beha.2021.101257. Epub 2021 Feb 13. PMID: 33762111.
Copy Download .nbib Format: NLM
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.

Journal of cancer research and clinical oncology

Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, Hilgendorf I, Hochhaus A, Scholl S.
PMID: 34297206
J Cancer Res Clin Oncol. 2021 Jul 23; doi: 10.1007/s00432-021-03733-0. Epub 2021 Jul 23.

BACKGROUND: Acute myeloid leukemia (AML) with antecedent hematological disease (s-AML) and treatment-related AML (t-AML) predicts poor prognosis. Intensive treatment protocols of those high-risk patients should consider allogeneic stem cell transplantation (allo-HSCT) in first complete remission (CR). Despite allo-HSCT, relapse...

Cite
Fleischmann M, Schnetzke U, Frietsch JJ, et al. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. J Cancer Res Clin Oncol. 2021;doi: 10.1007/s00432-021-03733-0.
Fleischmann, M., Schnetzke, U., Frietsch, J. J., Sayer, H. G., Schrenk, K., Hammersen, J., Glaser, A., Hilgendorf, I., Hochhaus, A., & Scholl, S. (2021). Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Journal of cancer research and clinical oncology, . https://doi.org/10.1007/s00432-021-03733-0
Fleischmann, Maximilian, et al. "Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia." Journal of cancer research and clinical oncology vol. (2021). doi: https://doi.org/10.1007/s00432-021-03733-0
Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, Hilgendorf I, Hochhaus A, Scholl S. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. J Cancer Res Clin Oncol. 2021 Jul 23; doi: 10.1007/s00432-021-03733-0. Epub 2021 Jul 23. PMID: 34297206.
Copy Download .nbib Format: NLM
Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines.

International journal of biological macromolecules

Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, Mohandas D, Somasekharan JV, Thavarool Puthiyedathu S.
PMID: 34973988
Int J Biol Macromol. 2021 Dec 30;199:150-161. doi: 10.1016/j.ijbiomac.2021.12.070. Epub 2021 Dec 30.

Anticancer drug cytarabine, has been widely used for treating haematological malignancies while it has minimal activity against solid tumours, which demands continuous infusion leading to high dose cytarabine toxicity. In this study, folate conjugated chitosan nanoparticles (FCCNP) were used...

Cite
Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, et al. Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. Int J Biol Macromol. 2021;199:150-161doi: 10.1016/j.ijbiomac.2021.12.070.
Geethakumari, D., Bhaskaran Sathyabhama, A., Raji Sathyan, K., Mohandas, D., Somasekharan, J. V., & Thavarool Puthiyedathu, S. (2021). Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. International journal of biological macromolecules, 199150-161. https://doi.org/10.1016/j.ijbiomac.2021.12.070
Geethakumari, Deepa, et al. "Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines." International journal of biological macromolecules vol. 199 (2021): 150-161. doi: https://doi.org/10.1016/j.ijbiomac.2021.12.070
Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, Mohandas D, Somasekharan JV, Thavarool Puthiyedathu S. Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. Int J Biol Macromol. 2021 Dec 30;199:150-161. doi: 10.1016/j.ijbiomac.2021.12.070. Epub 2021 Dec 30. PMID: 34973988.
Copy Download .nbib Format: NLM
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course.

Cancers

Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR.
PMID: 34885231
Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236122.

Although treatment options of acute myeloid leukemia (AML) have improved over the recent years, prognosis remains poor. Better understanding of the molecular mechanisms influencing and predicting treatment efficacy may improve disease control and outcome. Here we studied the expression,...

Cite
Clar KL, Weber LM, Schmied BJ, et al. Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236122.
Clar, K. L., Weber, L. M., Schmied, B. J., Heitmann, J. S., Marconato, M., Tandler, C., Schneider, P., & Salih, H. R. (2021). Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers, 13(23), . https://doi.org/10.3390/cancers13236122
Clar, Kim L, et al. "Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236122
Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR. Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236122. PMID: 34885231; PMCID: PMC8657109.
Copy Download .nbib Format: NLM
Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells.

International journal of molecular sciences

Wang SY, Shih YH, Shieh TM, Tseng YH.
PMID: 35008789
Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010361.

Over half of older patients with acute myeloid leukemia (AML) do not respond to cytotoxic chemotherapy, and most responders relapse because of drug resistance. Cytarabine is the main drug used for the treatment of AML. Intensive treatment with high-dose...

Cite
Wang SY, Shih YH, Shieh TM, et al. Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010361.
Wang, S. Y., Shih, Y. H., Shieh, T. M., & Tseng, Y. H. (2021). Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010361
Wang, Shuo-Yu, et al. "Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010361
Wang SY, Shih YH, Shieh TM, Tseng YH. Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010361. PMID: 35008789; PMCID: PMC8745175.
Copy Download .nbib Format: NLM
Showing 745 to 756 of 756 entries